Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance
Authors:
- Maria Cristina RapanottiMRMaria Cristina Rapanotti
- Elisa CuginiECElisa Cugini
- Elena CampioneElena Campione
- Cosimo Di RaimondoCRCosimo Di Raimondo
- Gaetana CostanzaGaetana Costanza
- Piero RossiPRPiero Rossi
- Amedeo FerlosioAFAmedeo Ferlosio
- Sergio BernardiniSBSergio Bernardini
- Augusto OrlandiAOAugusto Orlandi
- Anastasia De LucaALAnastasia De Luca
- Luca BianchiLBLuca Bianchi
Open Access
- 22 July 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11792
Abstract
The most promising method for monitoring patients with minimal morbidity is the detection of circulating melanoma cells (CMCs). We have shown that CD45−CD146+ABCB5+ CMCs identify a rare primitive stem/mesenchymal CMCs population associated with disease progression. The epithelial-to-mesenchymal transition (EMT) confers cancer cells a hybrid epithelial/mesenchymal phenotype promoting metastatization. Thus, we investigated the potential clinical value of the EMT gene signature of these primitive CMCs. A reliable quantitative real-time polymerase chain reaction (qRT-PCR) protocol was settled up using tumor cell lines RNA dilutions. Afterwards, immune-magnetically isolated CMCs from advanced melanoma patients, at onset and at the first checkpoint (following immune or targeted therapy), were tested for the level of EMT hallmarks and EMT transcription factor genes. Despite the small cohort of patients, we obtained promising results. Indeed, we observed a deep gene rewiring of the EMT investigated genes: in particular we found that the EMT gene signature of isolated CMCs correlated with patients’ clinical outcomes. In conclusion, We established a reliable qRT-PCR protocol with high sensitivity and specificity to characterize the gene expression of isolated CMCs. To our knowledge, this is the first evidence demonstrating the impact of immune or targeted therapies on EMT hallmark gene expressions in CMCs from advanced melanoma patients.Keywords
Funding Information
- University of Rome Tor Vergata (E83C22002880005)
This publication has 108 references indexed in Scilit:
- Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast CancerMolecular Cancer Therapeutics, 2012
- Slug Expression during Melanoma ProgressionThe American Journal of Pathology, 2012
- Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transitionBMC Cancer, 2012
- CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancerProceedings of the National Academy of Sciences, 2011
- Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapyInternational Journal of Cancer, 2011
- Identification of cells initiating human melanomasNature, 2008
- Increased expression of stem cell markers in malignant melanomaLaboratory Investigation, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- The genetics of malignant melanoma: lessons from mouse and manNature Reviews Cancer, 2003
- Multistep Nature of Metastatic InefficiencyThe American Journal of Pathology, 1998